Literature DB >> 27133592

Insights into the structure-activity relationship of the anticancer compound ZJ-101: A critical role played by the cyclohexene ring.

Aashay K Shah1, Shan Qian1, Dawei Zhang1, Sarah A Head2, Jun O Liu3, Zhendong Jin4.   

Abstract

Compound ZJ-101, a structurally simplified analog of the marine natural product superstolide A, was previously developed in our laboratory. In the subsequent structure-activity relationship study, a new analog ZJ-102 was designed and synthesized to probe the importance of the cyclohexenyl group through its replacement to a phenyl group using a concise and convergent synthetic approach. The biological evaluation showed that this new analog ZJ-102 is significantly less active against cancer cells in vitro than ZJ-101, suggesting that the cyclohexenyl ring (along with its two stereogenic centers) present in ZJ-101 is important for its anticancer activity.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anticancer agent; Asymmetric synthesis; Drug design; Structure–activity relationship; Superstolide A analog

Mesh:

Substances:

Year:  2016        PMID: 27133592     DOI: 10.1016/j.bmcl.2016.04.044

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  2 in total

1.  Insights into the structure-activity relationship of the anticancer compound ZJ-101, a derivative of marine natural product superstolide A: A critical role played by the conjugated trienyl lactone moiety.

Authors:  Shan Qian; Aashay K Shah; Sarah A Head; Jun O Liu; Zhendong Jin
Journal:  Bioorg Med Chem Lett       Date:  2016-06-22       Impact factor: 2.823

2.  The cyclohexene derivative MC-3129 exhibits antileukemic activity via RhoA/ROCK1/PTEN/PI3K/Akt pathway-mediated mitochondrial translocation of cofilin.

Authors:  Yi Zheng; Qin Ouyang; Ruoqiu Fu; Lei Liu; Hongwei Zhang; Xiaoye Hu; Yanxia Liu; Yingchun Chen; Ning Gao
Journal:  Cell Death Dis       Date:  2018-05-29       Impact factor: 8.469

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.